Search results
Showing 736 to 750 of 8219 results
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
All NICE products on adult's social care. Includes any guidance and quality standards.
All NICE products on lung cancer. Includes any guidance, advice and quality standards.
This webpage covers all NICE's guidelines on mental health. The table presents the guidelines alphabetically. Updates planned or in progress are...
All NICE products on hepatitis. Includes any guidance, advice and quality standards.
All NICE products on delirium. Includes any guidance and quality standards.
All NICE products on dementia. Includes any guidance and quality standards.
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
All NICE products on penile and testicular cancer. Includes any guidance and quality standards.
In development Reference number: GID-TA11504 Expected publication date: 04 February 2026
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure
In development Reference number: GID-DG10087 Expected publication date: 05 February 2026
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA867
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA899